Literature DB >> 19910745

Persistent hematuria after induction of remission in Wegener granulomatosis: a therapeutic dilemma.

Marina N Magrey1, Alexandra Villa-Forte, Curry L Koening, Jonathan L Myles, Gary S Hoffman.   

Abstract

Wegener granulomatosis (WG) is a systemic disease that is often associated with an immune-mediated form of glomerulonephritis (GN). Renal disease most often manifests as microscopic hematuria with or without red blood cell or mixed cellular casts, proteinuria, and an elevated serum creatinine concentration.We conducted the current study to determine whether persistent hematuria, in the setting of apparent clinical remission, may reflect glomerular injury and not active renal disease. We performed a retrospective analysis of data from 82 patients with new-onset WG, of whom 25 had GN at presentation.Twenty of 25 patients with GN achieved sustained remissions (>6 consecutive months' duration). During initial periods of active disease the median peak serum creatinine was 1.9 mg/dL (range, 0.6-13.6 mg/dL). The median time to remission was 4 months (range, 2-13 mo). After effective therapy, median creatinine was 1.1 mg/dL (range, 0.4-1.8 mg/dL). Ten of 20 patients had prolonged hematuria over a period of >6 months. Within this subset, 5 subsequently normalized urine over a median period of 11 months and 5 did not achieve normal urine sediment over a median follow-up of 38 months. Thus, 10 of 25 patients with WG and GN had sustained hematuria in spite of apparent prolonged clinical remission.Patients with WG and GN may achieve enduring remissions that allow withdrawal of medications in spite of continued microscopic hematuria with or without red blood cell casts that may persist for months or even years. Continued use of aggressive immunosuppressive therapies in such patients would be ill-advised and could lead to irreversible and even life-threatening side effects from cyclophosphamide or high-dose corticosteroids.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19910745     DOI: 10.1097/MD.0b013e3181c101cc

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  10 in total

1.  urinary biomarkers in relapsing antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Jason G Lieberthal; David Cuthbertson; Simon Carette; Gary S Hoffman; Nader A Khalidi; Curry L Koening; Carol A Langford; Kathleen Maksimowicz-McKinnon; Philip Seo; Ulrich Specks; Steven R Ytterberg; Peter A Merkel; Paul A Monach
Journal:  J Rheumatol       Date:  2013-04-01       Impact factor: 4.666

2.  The Search for a Biomarker of Relapse in ANCA-Associated Vasculitis.

Authors:  Meghan E Free; Ronald J Falk
Journal:  J Am Soc Nephrol       Date:  2016-05-09       Impact factor: 10.121

Review 3.  Biomarkers in vasculitis.

Authors:  Paul A Monach
Journal:  Curr Opin Rheumatol       Date:  2014-01       Impact factor: 5.006

Review 4.  Update on ANCA-associated vasculitis: from biomarkers to therapy.

Authors:  Martina Tedesco; Maurizio Gallieni; Francesca Pellegata; Mario Cozzolino; Federico Alberici
Journal:  J Nephrol       Date:  2019-07-12       Impact factor: 3.902

5.  Hematuria duration does not predict kidney function at 1 year in ANCA-associated glomerulonephritis.

Authors:  Teresa K Chen; Christine Murakami; Rebecca L Manno; Duvuru Geetha
Journal:  Semin Arthritis Rheum       Date:  2014-03-28       Impact factor: 5.532

6.  The Utility of Urinalysis in Determining the Risk of Renal Relapse in ANCA-Associated Vasculitis.

Authors:  Rennie L Rhee; John C Davis; Linna Ding; Fernando C Fervenza; Gary S Hoffman; Cees G M Kallenberg; Carol A Langford; W Joseph McCune; Paul A Monach; Philip Seo; Robert Spiera; E William St Clair; Ulrich Specks; John H Stone; Peter A Merkel
Journal:  Clin J Am Soc Nephrol       Date:  2018-01-25       Impact factor: 8.237

7.  Effect of hematuria on the outcome of immunoglobulin A nephropathy with proteinuria.

Authors:  Chihiro Iwasaki; Takahito Moriyama; Kayu Tanaka; Takashi Takei; Kosaku Nitta
Journal:  J Nephropathol       Date:  2016-02-25

8.  Current and novel biomarkers in anti-neutrophil cytoplasm-associated vasculitis.

Authors:  Juliana Bordignon Draibe; Xavier Fulladosa; Josep Maria Cruzado; Joan Torras; Alan David Salama
Journal:  Clin Kidney J       Date:  2016-06-29

9.  Persistent hematuria in patients with antineutrophil cytoplasmic antibody-associated vasculitis during clinical remission: chronic glomerular lesion or low-grade active renal vasculitis?

Authors:  Li Lv; Dong-Yuan Chang; Zhi-Ying Li; Min Chen; Zhao Hu; Ming-Hui Zhao
Journal:  BMC Nephrol       Date:  2017-12-06       Impact factor: 2.388

10.  Urinary Soluble CD163 in Active Renal Vasculitis.

Authors:  Vincent P O'Reilly; Limy Wong; Claire Kennedy; Louise A Elliot; Shane O'Meachair; Alice Marie Coughlan; Eoin C O'Brien; Michelle M Ryan; Diego Sandoval; Emma Connolly; Gerjan J Dekkema; Jiaying Lau; Wayel H Abdulahad; Jan-Stephan F Sanders; Peter Heeringa; Colm Buckley; Cathal O'Brien; Stephen Finn; Clemens D Cohen; Maja T Lindemeyer; Fionnuala B Hickey; Paul V O'Hara; Conleth Feighery; Sarah M Moran; George Mellotte; Michael R Clarkson; Anthony J Dorman; Patrick T Murray; Mark A Little
Journal:  J Am Soc Nephrol       Date:  2016-03-03       Impact factor: 10.121

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.